RecruitingPhase 2

L-Carnitine Protective Effect in Nephrotoxicity

Egypt46 participantsStarted 2025-08-10

Plain-language summary

The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female patients. * Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy. * Age between 18 and 75 years. * No serious cardiopulmonary comorbidity which could impair involvement in the study. * Creatinine clearance value above 50 mL/min/1.73 m². * Patients who will scheduled to receive at least 3 cycles of cisplatin. * Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure). Exclusion Criteria: * Pregnancy or lactation. * Metastasis to the central nervous system. * Psychiatric disorders. * Prior treatment with platinum derivatives. * Hypersensitivity to cisplatin, carboplatin or other platinum derivatives. * Patients with active infection or any symptoms of sepsis. * Acute renal failure or renal surgery within the last 3 months. * Patients unfit for cisplatin (patients with impaired renal function, sensorineural hearing loss and cardiomyopathy). * Patients with known history or current treatment with nephrotoxic agents. * Taking other antioxidant supplements such as Vitamins C and E.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

change in serum creatinine and creatinine clearance

Timeframe: Baseline (before chemotherapy cycles)

Trial details

NCT IDNCT07108777

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-01

Contact for this trial

Fatma M Eweda, Master

+201017045245 fatma.mamdouh7376@phrm.menofia.edu.eg

View on ClinicalTrials.gov More Nephrotoxicity trials